Immune cells engineered to fight childhood cancers enter first human tests

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called B7H3 found on many solid tumors. The main goals are to see if the treatment is safe, find the best dose, and measure how long the modified cells stay in the body. Some patients also receive a second type of modified cell or an additional drug to boost the immune response.